文献速递淋巴瘤造血干细胞移植与细胞治疗

CD8 T细胞耗竭关联CAR T细胞治疗失败,非αIL2受体激动剂可缓解

CD8 T-cell exhaustion linked with CAR T-cell failure can be mitigated by a non-alpha IL2 receptor agonist.
PubMed 文献 · Blood · 2026-10-23

该研究通过对CAR T细胞治疗进展后的肿瘤进行单细胞RNA测序,发现部分肿瘤中存在克隆扩增且增殖的CAR T细胞,这些细胞获得功能障碍的转录特征,提示持续的肿瘤细胞接触和慢性刺激。体外重复刺激模型显示CAR T细胞肿瘤控制失败,伴随T细胞功能障碍转录特征和IL2信号减少;非αIL2受体激动剂pegenzileukin可预防CAR T细胞功能障碍,改善T细胞扩增和肿瘤控制。体内模型中,单独CAR T细胞导致短暂反应后进展和继发中枢神经系统复发,而联合pegenzileukin可实现肿瘤完全清除。

要点

  • CAR T细胞治疗进展后的肿瘤中可检测到克隆扩增且增殖但功能失调的CAR T细胞。
  • 非αIL2受体激动剂pegenzileukin在体外可预防CAR T细胞功能障碍并改善肿瘤控制。
  • 体内模型中联合pegenzileukin可实现肿瘤完全清除,为克服T细胞耗竭提供临床前依据。

核心结论

  • CD8 T细胞耗竭与CAR T细胞治疗失败相关,非αIL2受体激动剂pegenzileukin可缓解这一过程。

研究设计与样本

  • 对CAR T细胞治疗进展后的肿瘤进行单细胞RNA测序。
  • 建立体外重复刺激模型模拟CAR T细胞功能障碍。
  • 从CAR T治疗后进展肿瘤建立细胞系模型进行体内验证。

主要发现

  • 进展肿瘤中部分存在克隆扩增且增殖的CAR T细胞,获得功能障碍转录特征。
  • 体外重复刺激导致CAR T细胞肿瘤控制失败,伴T细胞功能障碍转录特征和IL2信号减少。
  • Pegenzileukin在体外预防CAR T细胞功能障碍,改善T细胞扩增和肿瘤控制。
  • 体内单独CAR T细胞导致短暂反应后进展和继发中枢神经系统复发,联合pegenzileukin实现肿瘤完全清除。

临床怎么用

  • 非αIL2受体激动剂联合CAR T细胞可能克服T细胞耗竭相关的治疗失败。

局限性

  • 研究为临床前体外和体内模型,尚未在患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell (CART19) therapy represents a breakthrough for relapsed or refractory large B-cell lymphoma (rrLBCL). However, suboptimal CART19 activity can lead to therapeutic failure and dismal outcomes. Through single cell RNA-sequencing of tumors at the time of progression from CART19, we show that a subset of tumor contain clonally expanded and proliferating populations of CART19 cells that acquire transcriptional features of dysfunction, suggestive of ongoing tumor cell engagement and chronic stimulation. Using an in vitro system to model this process, we show that iterative rechallenge of CART19 cells with target cells drives failure of tumor control associated with acquired transcriptomic features of T-cell dysfunction and reduced IL2 signaling. Pegenzileukin, a non-alpha IL2-receptor agonist, prevented CART19 dysfunction, improving T-cell expansion and tumor control in vitro. To test this concept in vivo, we developed a cell line model from a post-CART19 progression tumor that reproduces the response and failure kinetics observed in the originating patient. In vivo CART19 alone led to transient response followed by progression and secondary central nervous system relapse in this model, while the addition of pegenzileukin to CART19 led to the complete eradication of tumors. This provides mechanism-informed pre-clinical rationale for the use of non-alpha IL2 receptor agonists in combating T-cell exhaustion, a critical mechanism of CART19 failure.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Arita K, Dai E, Li X, et al. CD8 T-cell exhaustion linked with CAR T-cell failure can be mitigated by a non-alpha IL2 receptor agonist. Blood. 2026. PMID: 42913488. doi:10.1182/blood.2026033885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。